Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate

Pedro Such,1 José Manuel Olivares,2 Lizbeth Arias,1 Mette Troels Berg,1 Jessica Madera3 1Medical Strategy and Communication, H. Lundbeck A/S, Valby, 2500, Denmark; 2Department of Psychiatry, Hospital Álvaro Cunqueiro, Health Research Institute Galicia Sur (IISGS), CIBERSAM, Vig...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Such P, Olivares JM, Arias L, Troels Berg M, Madera J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	antipsychotic treatment aripiprazole aripiprazole once-monthly injectable (aom) long-acting injectable paliperidone palmitate once-monthly injectable (pp1m) patient outcomes real world schizophrenia survey.sychotic treatment paliperidone palmitate Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/be1804f3003d4740995def02a5be3a7a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:be1804f3003d4740995def02a5be3a7a
record_format	dspace
spelling	oai:doaj.org-article:be1804f3003d4740995def02a5be3a7a2021-12-02T15:47:51ZOnline Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate1178-2021https://doaj.org/article/be1804f3003d4740995def02a5be3a7a2021-06-01T00:00:00Zhttps://www.dovepress.com/online-survey-of-clinical-practice-in-patients-with-schizophrenia-trea-peer-reviewed-fulltext-article-NDThttps://doaj.org/toc/1178-2021Pedro Such,1 José Manuel Olivares,2 Lizbeth Arias,1 Mette Troels Berg,1 Jessica Madera3 1Medical Strategy and Communication, H. Lundbeck A/S, Valby, 2500, Denmark; 2Department of Psychiatry, Hospital Álvaro Cunqueiro, Health Research Institute Galicia Sur (IISGS), CIBERSAM, Vigo, Spain; 3Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, New Jersey, 08540, USACorrespondence: Pedro SuchMedical Strategy and Communication, H. Lundbeck A/S, Ottiliavej 9, Valby, 2500, DenmarkTel +45 3630 1311Email PSU@lundbeck.comBackground: To obtain real-world evidence of functional improvements during atypical long-acting injectable (aLAI) therapy in recent-onset schizophrenia, an online survey was conducted to assess the impact of aripiprazole once-monthly injectable 400 mg (AOM 400; partial D2 receptor agonist) and paliperidone palmitate once-monthly (PP1M; injectable, full D2 receptor antagonist).Methods: Psychiatrists provided data for their 2 most recent AOM 400 patients, 2 most recent PP1M patients. Survey included 2000 patient cases (1000 AOM 400; 1000 PP1M). Eligible patients were aged 18– 35 years, had been diagnosed with schizophrenia within 5 years, received AOM 400 or PP1M continuously for ≥ 6 months according to approved labels (mean durations: 1.6 and 1.7 years with AOM 400 and PP1M, respectively). Assessments included Global Assessment of Functioning (GAF) Scale, Personal and Social Performance Scale, Positive and Negative Syndrome Scale, and Quality of Life Scale. GAF assessments were done retrospectively and also at the time of survey.Results: Baseline mean GAF scores were 43.3 and 43.8 for AOM 400 and PP1M, respectively, indicating serious symptoms/functional impairment in both groups. Mean improvements following AOM 400 and PP1M therapy were 19.7 and 16.3 points, respectively (final scores in mild functional impairment category). Other measures assessing symptoms/functionality/quality of life demonstrated the benefits of long-term aLAI therapy.Conclusion: Schizophrenia patients with serious functional impairment prior to current aLAI treatment showed improvements in functional outcome after AOM 400 or PP1M therapy. These results suggest functional improvements with aLAIs are apparent not only in research but also real-world settings.Keywords: antipsychotic treatment, aripiprazole, aripiprazole once-monthly injectable, AOM, long-acting injectable, paliperidone palmitate once-monthly injectableSuch POlivares JMArias LTroels Berg MMadera JDove Medical Pressarticleantipsychotic treatmentaripiprazolearipiprazole once-monthly injectable (aom)long-acting injectablepaliperidone palmitate once-monthly injectable (pp1m)patient outcomesreal worldschizophreniasurvey.sychotic treatmentaripiprazolelong-acting injectablepaliperidone palmitatepatient outcomesreal worldNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 1881-1892 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antipsychotic treatment aripiprazole aripiprazole once-monthly injectable (aom) long-acting injectable paliperidone palmitate once-monthly injectable (pp1m) patient outcomes real world schizophrenia survey.sychotic treatment aripiprazole long-acting injectable paliperidone palmitate patient outcomes real world Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	antipsychotic treatment aripiprazole aripiprazole once-monthly injectable (aom) long-acting injectable paliperidone palmitate once-monthly injectable (pp1m) patient outcomes real world schizophrenia survey.sychotic treatment aripiprazole long-acting injectable paliperidone palmitate patient outcomes real world Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Such P Olivares JM Arias L Troels Berg M Madera J Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
description	Pedro Such,1 José Manuel Olivares,2 Lizbeth Arias,1 Mette Troels Berg,1 Jessica Madera3 1Medical Strategy and Communication, H. Lundbeck A/S, Valby, 2500, Denmark; 2Department of Psychiatry, Hospital Álvaro Cunqueiro, Health Research Institute Galicia Sur (IISGS), CIBERSAM, Vigo, Spain; 3Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization, Inc, Princeton, New Jersey, 08540, USACorrespondence: Pedro SuchMedical Strategy and Communication, H. Lundbeck A/S, Ottiliavej 9, Valby, 2500, DenmarkTel +45 3630 1311Email PSU@lundbeck.comBackground: To obtain real-world evidence of functional improvements during atypical long-acting injectable (aLAI) therapy in recent-onset schizophrenia, an online survey was conducted to assess the impact of aripiprazole once-monthly injectable 400 mg (AOM 400; partial D2 receptor agonist) and paliperidone palmitate once-monthly (PP1M; injectable, full D2 receptor antagonist).Methods: Psychiatrists provided data for their 2 most recent AOM 400 patients, 2 most recent PP1M patients. Survey included 2000 patient cases (1000 AOM 400; 1000 PP1M). Eligible patients were aged 18– 35 years, had been diagnosed with schizophrenia within 5 years, received AOM 400 or PP1M continuously for ≥ 6 months according to approved labels (mean durations: 1.6 and 1.7 years with AOM 400 and PP1M, respectively). Assessments included Global Assessment of Functioning (GAF) Scale, Personal and Social Performance Scale, Positive and Negative Syndrome Scale, and Quality of Life Scale. GAF assessments were done retrospectively and also at the time of survey.Results: Baseline mean GAF scores were 43.3 and 43.8 for AOM 400 and PP1M, respectively, indicating serious symptoms/functional impairment in both groups. Mean improvements following AOM 400 and PP1M therapy were 19.7 and 16.3 points, respectively (final scores in mild functional impairment category). Other measures assessing symptoms/functionality/quality of life demonstrated the benefits of long-term aLAI therapy.Conclusion: Schizophrenia patients with serious functional impairment prior to current aLAI treatment showed improvements in functional outcome after AOM 400 or PP1M therapy. These results suggest functional improvements with aLAIs are apparent not only in research but also real-world settings.Keywords: antipsychotic treatment, aripiprazole, aripiprazole once-monthly injectable, AOM, long-acting injectable, paliperidone palmitate once-monthly injectable
format	article
author	Such P Olivares JM Arias L Troels Berg M Madera J
author_facet	Such P Olivares JM Arias L Troels Berg M Madera J
author_sort	Such P
title	Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
title_short	Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
title_full	Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
title_fullStr	Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
title_full_unstemmed	Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
title_sort	online survey of clinical practice in patients with schizophrenia treated with long-acting injectable aripiprazole or paliperidone palmitate
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/be1804f3003d4740995def02a5be3a7a
work_keys_str_mv	AT suchp onlinesurveyofclinicalpracticeinpatientswithschizophreniatreatedwithlongactinginjectablearipiprazoleorpaliperidonepalmitate AT olivaresjm onlinesurveyofclinicalpracticeinpatientswithschizophreniatreatedwithlongactinginjectablearipiprazoleorpaliperidonepalmitate AT ariasl onlinesurveyofclinicalpracticeinpatientswithschizophreniatreatedwithlongactinginjectablearipiprazoleorpaliperidonepalmitate AT troelsbergm onlinesurveyofclinicalpracticeinpatientswithschizophreniatreatedwithlongactinginjectablearipiprazoleorpaliperidonepalmitate AT maderaj onlinesurveyofclinicalpracticeinpatientswithschizophreniatreatedwithlongactinginjectablearipiprazoleorpaliperidonepalmitate
_version_	1718385774442840064

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate

Ejemplares similares